Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Blue Sky MD vs Iron Med RX

Blue Sky MD
Graded #170

Higher grade

vs+12.700000000000003
Iron Med RX
Graded #454

Lower grade

The verdict

Blue Sky MD takes it — 67.5/100 to 54.8/100.

Blue Sky MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Blue Sky MD is a LegitScript-certified medical weight-loss practice founded in 2008 with seven North Carolina clinics and telehealth visits available.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBlue Sky MD +19
64
45
Dose & formulationBlue Sky MD +13
64
51
Clinical oversightBlue Sky MD +16
87
71
Labs & monitoringBlue Sky MD +10
62
52
FulfillmentBlue Sky MD +5
63
58
Contract termsEven
55
55
Blue Sky MD · left barIron Med RX · right bar

The numbers

MetricBlue Sky MDIron Med RX
WeighScore67.5/10054.8/100
GradeCC
Scorecard rank#170#454
Semaglutide$160/mo (starting dose, compounded)Not disclosed
Tirzepatide$240/mo (starting dose, compounded)Not disclosed
Coverage1 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Blue Sky MD

Graded #170 · C

Strengths

  • LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
  • Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
  • Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
  • Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
  • Insurance accepted in many cases; affordable self-pay options for uninsured patients

Where it loses points

  • Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
  • Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
  • Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
  • No explicit lab testing protocol published; online FAQ does not confirm labs are included
  • Small regional provider vs. national platforms; limited provider footprint outside North Carolina
Iron Med RX

Graded #454 · C

Strengths

  • Unusually broad GLP-1 lineup — compounded semaglutide and tirzepatide in both oral tablets and injection, plus microdosing and longevity add-ons
  • Online process with licensed-provider oversight, virtual consults, progress tracking and home delivery
  • Oral tablet options for people who would rather not inject

Where it loses points

  • Prices are not shown publicly — you only see costs after creating an account, so you cannot compare value upfront
  • Labels its oral semaglutide 'research-grade' — wording usually tied to research/non-prescription peptides; confirm it is prescribed for human use
  • Does not name its compounding pharmacy or list the states it serves; the listed address is a private mailbox (PMB), not a clinic
  • Compounded GLP-1 only — no brand-name or insurance options; small, lightly documented operation

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard